Health | WPN World People News

Researchers at Memorial Sloan Kettering Cancer Center have shown that autologous fecal microbiota transplantation (auto-FMT) is a safe and effective way to help replenish beneficial gut bacteria in cancer patients who require intense antibiotics during allogenic hematopoietic stem cell transplantation.

The United States, on September 25, announced during the United Nations (UN) General Assembly in New York, The AMR Challenge—the most ambitious global initiative to date to combat the growing threat of antibiotic resistance (AR or AMR).

Reported cases of congenital syphilis – syphilis passed from a mother to her baby during pregnancy or delivery – have more than doubled since 2013, according to the annual Sexually Transmitted Disease Surveillance Report released by the Centers for Disease Control and Prevention (CDC), on September 25. The data underscore the need for all pregnant women to receive early prenatal care that includes syphilis testing at their first visit and follow-up testing for women at high risk of infection.

On September 24, the U.S. Environmental Protection Agency asked the Ninth Circuit Court of Appeals to rehear the case in which it decided that the EPA must ban chlorpyrifos within 60 days.

A new action plan outlining measures to prevent and treat tuberculosis (TB) in children and adolescents was launched by global tuberculosis (TB) leadership in advance of the United Nations General Assembly High-Level meeting on TB on September 24, 2018.

More than 3 million people died as a result of harmful use of alcohol in 2016, according a report released by the World Health Organization (WHO), on September 21. This represents 1 in 20 deaths. More than three quarters of these deaths were among men. Overall, the harmful use of alcohol causes more than 5% of the global disease burden.

On September 19, WHO published its first investment case, setting out the transformative impacts on global health and sustainable development that a fully-financed WHO could deliver over the next five years.

A clinical trial testing infusions of combination antibodies in people living with HIV has begun at the National Institutes of Health. The early phase clinical trial will evaluate whether periodic infusions of two highly potent, HIV-specific, broadly neutralizing antibodies (bNAbs)—3BNC117 and 10-1074—are safe in people living with HIV. The study also will gather preliminary data on how effectively the bNAb infusions, delivered together every two to four weeks, suppress HIV following discontinuation of antiretroviral therapy (ART).

Fewer people fell ill and died from tuberculosis (TB) last year but countries are still not doing enough to end TB by 2030, warns the World Health Organization (WHO). Although global efforts have averted an estimated 54 million TB deaths since 2000, TB remains the world’s deadliest infectious disease.